Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 43

Sort by

Sort Order Select

Journal Articles

Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19

Blood (2024) 144 (Supplement 1): 845.

https://doi.org/10.1182/blood-2024-201097

Published: 2024

Journal Articles

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Antonio M Risitano, Simona Iacobelli, Austin G. Kulasekararaj, Marleen Van Os, Sophie Terwel, Morag Griffin, Constantijn J.M. Halkes, Christian Recher, Fiorenza Barraco, Edouard Forcade, Carlos Vallejo, Beatrice Drexler, Jean-Baptiste Méar, Alexander Smith, Emanuele Angelucci, Reinier Raymakers, Marco R De Groot, Etienne Daguindau, Erfan Nur, Wilma Barcellini, Nigel H. Russell, Louis Terriou, Anna Paola Iori, Walter Barberi, Anna Sureda Balari, Isabel Sanchez-Ortega, Blanca Xicoy, Isidro Jarque Ramos, Jamie Cavenagh, Flore Sicre De Fontbrune, Camilla Frieri, Talha Munir, Jennifer Tjon, Suzanne Tavitian, Aline Praire, Laurence Clement, Florence Rabian, Luana Marano, Anita Hill, Elena Palmisani, Petra Muus, Serena Marotta, Fabiana Cacace, Marica Laurino, Jakob Passweg, Sr., Judith Marsh, Gerard Socie, Ghulam Mufti, Carlo Dufour, Regis Peffault De Latour

Blood (2024) 144 (Supplement 1): 302.

https://doi.org/10.1182/blood-2024-194699

Published: 2024

Journal Articles

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Blood (2024) 144 (7): 714–728.

https://doi.org/10.1182/blood.2024024310

Published: 2024

Includes: Supplemental data

Journal Articles

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

Blood (2024) 143 (19): 1931–1936.

https://doi.org/10.1182/blood.2023023096

Published: 2024

Includes: Supplemental data

Journal Articles

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panos Kottaridis, Claire Arnold, Ulrik Malthe Overgaard, Mike Dennis, Charlotte Wilhelm-Benartzi, Richard Dillon, Nigel Russell

Blood (2023) 142 (Supplement 1): 425.

https://doi.org/10.1182/blood-2023-179033

Published: 2023

Journal Articles

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

Blood (2023) 142 (Supplement 1): 2939.

https://doi.org/10.1182/blood-2023-179036

Published: 2023

Journal Articles

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Nigel H. Russell, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, Ulrik Malthe Overgaard, Amanda Gilkes, Jad Othman, Nicola Potter, Richard Dillon, Priyanka Mehta, Panagiotis Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Sylvie D Freeman, Mike Dennis

Blood (2022) 140 (Supplement 1): 526–528.

https://doi.org/10.1182/blood-2022-162377

Published: 2022

Journal Articles

Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

Jad Othman, Richard Dillon, Charlotte Wilhelm-Benartzi, Steve Knapper, Leona M Batten, Joanna Canham, Emily L Hinson, William Villiers, Michelle Kleeman, Amanda Gilkes, Nicola Potter, Ulrik Malthe Overgaard, Priyanka Mehta, Panos Kottaridis, Jamie Cavenagh, Claire Hemmaway, Claire Arnold, Mike Dennis, Nigel H. Russell

Blood (2022) 140 (Supplement 1): 1036–1038.

https://doi.org/10.1182/blood-2022-159433

Published: 2022

Journal Articles

Retinoic acid–responsive CD8 effector T cells are selectively increased in IL-23–rich tissue in gastrointestinal GVHD

Jennifer A. Ball, Andrew Clear, James Aries, Sarah Charrot, Caroline Besley, Matt Mee, Andrew Stagg, James O. Lindsay, Jamie Cavenagh, Maria Calaminci, John G. Gribben, Jeff Davies

Blood (2021) 137 (5): 702–717.

https://doi.org/10.1182/blood.2020005170

Published: 2021

Includes: Supplemental data

Journal Articles

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Blood (2020) 135 (9): 680–688.

https://doi.org/10.1182/blood.2019002959

Published: 2020

Includes: Supplemental data

Journal Articles

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Blood (2019) 134 (Supplement_1): 861.

https://doi.org/10.1182/blood-2019-127992

Published: 2019

Journal Articles

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Gordon Cook, Christopher Parrish, MBBChir, MRCP, FRCPath, MA, PhD, Kwee Yong, PhD, Jamie Cavenagh, MD PhD, John A Snowden, MD, Mark T Drayson, Mamta Garg, David Cairns, John Ashcroft, Alina Striha, Anna Hockaday, Ruth M De Tute, BSc,MSc, Roger G. Owen, Cathy Williams, Mark Cook, MBChB,PhD

Blood (2018) 132 (Supplement 1): 255.

https://doi.org/10.1182/blood-2018-99-112116

Published: 2018

Journal Articles

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

Richard Dillon, MA, PhD MRCP, FRCPath, Robert K. Hills, MA, DPhil, MSc, Sylvie D Freeman, MBChB, DPhil, Nicola Potter, PhD, Adam Ivey, BSc, MSc, PhD, Jelena Jovanovic, PhD, Anju Kanda, MSc, Manohursingh Runglall, MSc, Nicola Foot, MSc, Laura Upton, Asim Khwaja, MD PhD, Jamie Cavenagh, MD PhD, Ruth Spearing, MD, Alan K. Burnett, MD, Nigel H. Russell, David Grimwade, PhD MRCP, MRCPath

Blood (2018) 132 (Supplement 1): 2739.

https://doi.org/10.1182/blood-2018-99-113662

Published: 2018

Journal Articles

Immune Microenvironment Analysis of Bone Marrow By Mass Cytometry and RNA Sequencing in Multiple Myeloma Patients Treated with Daratumumab and Durvalumab

Frances Seymour, MRCP, BSc, MBBS, Mary H Young, PhD, Mark Tometsko, BSc, Jamie Cavenagh, MD PhD, Ethan G. Thompson, PhD, Elizabeth Whalen, PhD, Sam A Danziger, Alison Fitch, Brian A. Fox, PhD, Andrew Dervan, Teri Foy, PhD, Katie Newhall, PhD, John G. Gribben

Blood (2018) 132 (Supplement 1): 3296.

https://doi.org/10.1182/blood-2018-99-114453

Published: 2018

Journal Articles

Characterising the Immunological Microenvironment in Newly Diagnosed Multiple Myeloma Bone Marrow By Time of Flight Cytometry Reveals Abnormalities in Antigen Presenting and Effector Lymphocyte Populations with Prognostic Significance

Frances Seymour, MRCP, BSc, MBBS, Jamie Cavenagh, MD PhD, John G. Gribben

Blood (2018) 132 (Supplement 1): 58.

https://doi.org/10.1182/blood-2018-99-114102

Published: 2018

Journal Articles

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Ruth M De Tute, BSc,MSc, Debbie Sherratt, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 802.

https://doi.org/10.1182/blood-2018-99-116426

Published: 2018

Journal Articles

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Kwee Yong, MD PhD, Samantha Hinsley, MSc, BSc, Debbie Sherratt, Jessica Kendall, BSc, MSc, Sarah R Brown, PhD MSc, BSc, Louise Flanagan, PhD, Catherine Williams, Jamie Cavenagh, MD PhD, Martin Kaiser, MD, Neil K Rabin, MD, Karthik Ramasamy, MD PhD, Mamta Garg, Holger W. Auner, MD PhD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Ruth M De Tute, BSc,MSc, Gareth Morgan, MD, Faith E. Davies, MD, Roger G. Owen

Blood (2018) 132 (Supplement 1): 306.

https://doi.org/10.1182/blood-2018-99-116624

Published: 2018

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Kwee Yong, PhD, Samantha Hinsley, Holger W. Auner, MD PhD, Debbie Sherratt, Ruth Mary De Tute, BSc,MSc, Sarah Brown, Louise Flanagan, Cathy Williams, Jamie Cavenagh, Martin F Kaiser, MD, Neil Rabin, Karthik Ramasamy, Mamta Garg, MD, Stephen F. Hawkins, MBChB, MRCP, Ceri Bygrave, MD FRCPath, MPhil, Gareth J. Morgan, MD PhD, Faith E. Davies, MD, Roger G Owen, MD

Blood (2017) 130 (Supplement 1): 835.

https://doi.org/10.1182/blood.V130.Suppl_1.835.835

Published: 2017

Journal Articles

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

Charles Craddock, Wendy Ingram, Daniel Slade, Andrea Hodgkinson, BSc(Hons),PhD, Francis J. Mussai, MA, MD DPhil, Carmela De Santo, Jamie Cavenagh, Michael Dennis, MDMRCP,FRCPath, Ram Malladi, MRCP, FRCPath, PhD, Shamyla Siddique, BSc.(Hons.), MPhil, Yap Christina, MSci, PhD CStat

Blood (2017) 130 (Supplement 1): 276.

https://doi.org/10.1182/blood.V130.Suppl_1.276.276

Published: 2017

Journal Articles

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Kwee L Yong, MBChB, PhD, Sarah Brown, Samantha Hinsley, Louise Flanagan, Neil Rabin, MB,BS, PhD, Karthik Ramasamy, Jamie Cavenagh, Roger G Owen, Martin F Kaiser, MD, Eric Low, Catherine Williams

Blood (2015) 126 (23): 1840.

https://doi.org/10.1182/blood.V126.23.1840.1840

Published: 2015

NARROW

Impact of Cytogenetics, Induction Chemotherapy and MRD on Outcomes of Intensively Treated AML with KMT2A Rearrangements - Experience from UK NCRI AML17 and AML19

Eltrombopag Added to Standard Immunosuppressive Treatment Improves Long-Term Outcomes As Front-Line Therapy for Severe Aplastic Anemia: Final 2-Year Analysis of EBMT-Saawp Race Study

Molecular, clinical, and therapeutic determinants of outcome in NPM1 -mutated AML

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission

The Benefit of Allogeneic Transplant in 1 st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction - an Analysis of the UK NCRI AML17 and AML19 Studies

Interaction between Presenting Features, Co-Occurring Mutations, MRD and Induction Treatment Influences Outcome in Adults with NPM1 Mutated AML - an Analysis of 1357 Patients in the UK NCRI AML17 and AML19 Studies

FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial

Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

Retinoic acid–responsive CD8 effector T cells are selectively increased in IL-23–rich tissue in gastrointestinal GVHD

Molecular MRD status and outcome after transplantation in NPM1 -mutated AML

Efficacy and Safety of Carfilzomib at 56mg/m 2 with Cyclophosphamide and Dexamethasone (K56Cd) in Newly Diagnosed Multiple Myeloma Patients Followed By ASCT or K56Cd Consolidation: Initial Results of the Phase 2 Cardamon Study

Ixazomib, Thalidomide and Dexamethasone Is an Effective and Well Tolerated Re-Induction Regimen Leading to Salvage Autologous Stem Cell Transplantation (sASCT): Results from the Re-Induction Interim Analysis of UK-MRA Myeloma XII (ACCoRD) Trial

Pre-Transplant NPM1 Mutant Transcript Level Is Highly Predictive of Outcome after Allograft and Thresholds Are Dependent on FLT3 ITD Status

Immune Microenvironment Analysis of Bone Marrow By Mass Cytometry and RNA Sequencing in Multiple Myeloma Patients Treated with Daratumumab and Durvalumab

Characterising the Immunological Microenvironment in Newly Diagnosed Multiple Myeloma Bone Marrow By Time of Flight Cytometry Reveals Abnormalities in Antigen Presenting and Effector Lymphocyte Populations with Prognostic Significance

Maintenance with Carfilzomib Following Carfilzomib, Cyclophosphamide and Dexamethasone at First Relapse or Primary Refractory Multiple Myeloma (MM) on the Phase 2 Muk Five Study: Effect on Minimal Residual Disease

Carfilzomib Versus Bortezomib in Combination with Cyclophosphamide and Dexamethasone for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): Outcomes Based on Genetic Risk and Long Term Follow up of the Phase 2 Muk Five Study

Carfilzomib, Cyclophosphamide and Dexamethasone (KCD) Versus Bortezomib, Cyclophosphamide and Dexamethasone (VCD) for Treatment of First Relapse or Primary Refractory Multiple Myeloma (MM): First Final Analysis of the Phase 2 Muk Five Study

Combined Azacitidine and High Dose Lenalidomide Therapy Is Well Tolerated and Clinically Active in Patients Who Relapse after Allogeneic Stem Cell Transplantation for Actue Myeloid Leukemia: Results of the Uk Trials Acceleration Programme Viola Trial

Carfilzomib, Cyclophosphamide and Dexamethasone Is Well Tolerated in Patients with Relapsed/Refractory Multiple Myeloma Who Have Received One Prior Regimen

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only